Picture2.JPG
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
February 15, 2024 08:00 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Picture2.JPG
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
February 06, 2024 07:30 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Picture2.JPG
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
January 08, 2024 07:30 ET | Vivos Therapeutics, Inc
Vivos Therapeutics is seeing positive preliminary metrics regarding FDA 510(k) clearance of its CARE oral medical devices to treat severe OSA.
Picture2.JPG
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”
December 11, 2023 07:30 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos DNA appliance®
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
November 29, 2023 07:30 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Picture2.JPG
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
November 14, 2023 16:05 ET | Vivos Therapeutics, Inc
Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare,...
Picture2.JPG
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
November 09, 2023 16:30 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Picture2.JPG
Vivos Therapeutics Closes $4 Million Private Placement
November 02, 2023 17:00 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Picture2.JPG
Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
October 31, 2023 08:00 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Picture2.JPG
Vivos Therapeutics Announces Reverse Stock Split
October 26, 2023 07:30 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...